Pharmafile Logo
Pharmafocus logo
Advanced Search

Transgene

Showing 11 posts of 11 posts found.

First patient dosed in Transgene and BioInvent’s phase 1 trial

October 10, 2023
Research and Development BioInvent, Oncology, Transgene, oncology, phase 1 trial

Transgene and BioInvent have announced that the first patient has been treated in the phase 1 part B clinical trial …

News
volodymyr-hryshchenko-m1hq4ibp9rc-unsplash

BioInvent and Transgene announce positive phase 1a solid tumour trial data

May 25, 2023
Research and Development BioInvent, Oncology, Transgene, clinical trials, oncology, tumours

Sweden-based BioInvent and French Transgene, both biotech companies, have reported positive phase 1a data from a trial studying BT-001 for …

News
shutterstock_gonnorrhea

Transgene ceases development of failed advanced non-squamous non-small cell lung cancer immunotherapy candidate

December 16, 2019
Research and Development, Sales and Marketing Cancer, Transgene, lung cancer, pharma

Cancer immunotherapeutics firm Transgene has confirmed that it is to terminate further development of its TG4010 candidate in the first-line …

News
shutterstock_159488225

Transgene terminates oncolytic IO combo trial in advanced liver cancer

August 8, 2019
Research and Development Cancer, Transgene, clinical trials, liver cancer, pharma

Biotech firm Transgene has announced its decision to terminate a study investigating the efficacy of its oncolytic immunotherapy product Pexa-Vec …

News
transgene

Transgene announce key partnership with Merck KGaA and Pfizer

October 12, 2016
Research and Development Cancer, France, Merck Group, Pfizer, Transgene, avelumab, head, neck

Transgene, a company that designs and developed targeted immunotherapies to treat cancer and infectious diseases, has announced a collaboration agreement …

News
sanofi image

Sanofi in immunotherapy tie-up

March 26, 2013
Research and Development, Sales and Marketing Transgene, snaofi

Sanofi has signed a 15-year deal with biopharma company Transgene to produce a platform to help create a range of …

News
2ca8123

Transgene appoints Nathalie Adda as chief medical officer

September 21, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Nathalie Adda, Transgene

Transgene has announced the appointment of Dr Nathalie Adda as chief medical officer. Responsible for medical and regulatory affairs of …

Appointment
Roche building

Roche pulls out of vaccine alliance with Transgene

February 23, 2011
Research and Development HPV, HPV vaccine, Roche, TG4001, Transgene, cervical cancer, cervical lesions, human papilloma virus, vaccines

Roche has terminated its license agreement with Transgene for its HPV therapeutic vaccine TG4001. The vaccine is currently being tested …

News

Transgene acquires rights to cancer vaccine

September 10, 2010
Research and Development JX-594, Jennerex, Transgene, cancer vaccine

French biotech company Transgene has acquired rights to commercialise a novel cancer vaccine that is being tested against multiple types …

News

Lung cancer vaccine poised to begin phase IIb/III trials

September 1, 2010
Research and Development NSCLC, TG4010, Transgene, cancer vaccine

French biotech firm Transgene has received positive scientific advice from the EMA for late stage trials of its new lung …

News

Novartis buys into Transgene’s lung cancer candidate

March 11, 2010
Research and Development Novartis, Transgene, immunotherapy, lung cancer

French biotech company Transgene has signed a deal with Novartis for the future development and marketing of its potential lung …

News

Latest content

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024

Intra-Cellular Therapies shares phase 3 results for major depressive disorder therapy

April 17, 2024

Novartis shares new data about Fabhalta for IgAN treatment

April 16, 2024